estradiol · Noven · NDA 203752
Minivelle
Earliest generic entry, as listed · earliest of 5 marketed strengths
4 Jul 2030
Blocked by patent: US 8231906.
Listed patents · 4 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 8231906 | drug substance, drug product · sets the listed date | 4 Jul 2030 |
| US 9724310 | drug substance, drug product | 10 Jul 2028 |
| US 9730900 | use U-2086 | 10 Jul 2028 |
| US 9833419 | drug product | 10 Jul 2028 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 5
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 203752 · 001 · RLD | film, extended release, transdermal | 0.0375MG/24HR | 4 Jul 2030 |
| 203752 · 002 · RLD | film, extended release, transdermal | 0.075MG/24HR | 4 Jul 2030 |
| 203752 · 003 · RLD | film, extended release, transdermal | 0.05MG/24HR | 4 Jul 2030 |
| 203752 · 004 · RLD | film, extended release, transdermal | 0.1MG/24HR | 4 Jul 2030 |
| 203752 · 005 · RLD | film, extended release, transdermal | 0.025MG/24HR | 4 Jul 2030 |